Information Provided By: 
Fly News Breaks for June 14, 2018
ARGX, GRFS
Jun 14, 2018 | 06:36 EDT
JPMorgan analyst James Gordon last night downgraded Grifols to Neutral from Overweight and lowered his price target for the shares to $25.50 from $26.30. With 5% downside to consensus expectations in 2019 and 2020, the shares now look fully valued, Gordon tells investors in a research note. Further, the analyst sees competitor clinical data from Argenx (ARGX) and UCB in the second half of 2018 potentially raising questions as to the long-term sustainability of the auto-immune element of Grifols' immuno-globulin franchise.
News For GRFS;ARGX From the Last 2 Days
